AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PERCHERON FPO

0.012

+0.0019.09%

Volume:5.29M

Turnover:56.56K

Market Cap:13.05M

PE:-0.75

High:0.012

Open:0.011

Low:0.010

Close:0.011

Loading ...

Overview Company News Filings

Ceres Plans to Cut Capital Costs, Boost Stock Price

MT Newswires Live

BRIEF-Percheron Therapeutics Submits Non-Binding Proposal To In-License New Clinic-Ready Drug Development Program

Percheron Therapeutics Submits Non-binding Licensing Proposal for Drug Development Program, Shares Jump 8%

MT Newswires Live

Percheron Therapeutics - Submits Non-Binding Proposal to in-License New Clinic-Ready Drug Development Program

THOMSON REUTERS

ResMed's half-year FY25 results: solid growth & expanding opportunities

Could 2025 be the year that valuations matter again?

ASX Small-Cap Stocks to Watch

MT Newswires Live

BRIEF-Percheron Therapeutics Seeks Trading Halt Pending In Relation To Initial Top Line Data For Company's Phase IIB Clinical Trial

Percheron Therapeutics Ltd - Trading Halt Pending in Relation to Initial Top Line Data for Company's Phase Iib Clinical Trial

THOMSON REUTERS

Percheron Therapeutics Discontinues American Depository Receipt Facility, Uplists to OTCQB

MT Newswires Live

Percheron Therapeutics Advances Phase 2b Muscular Dystrophy Clinical Trial; Shares Down 3%

MT Newswires Live

Percheron Therapeutics - Completion of Share Purchase Plan to Raise up to a$2 Mln

THOMSON REUTERS

3 Promising ASX Penny Stocks With Market Caps Over A$70M

Simply Wall St.

Is it madness to buy CBA shares now?

Percheron Therapeutics Ltd-Percheron Launches Post-Trial Access Program

THOMSON REUTERS

Percheron Therapeutics Ltd-Share Purchase Plan Offer Booklet

THOMSON REUTERS

Percheron Therapeutics Ltd-Percheron to Launch Share Purchase Plan

THOMSON REUTERS

BRIEF-Percheron Therapeutics Says A$13 Mln Institutional Placement At A$0.08 Per New Share

BUZZ-Australia's Percheron Therapeutics plunges on discounted placement

Percheron Therapeutics - a$13.0 Mln Institutional Placement at a Price of a$0.08 per New Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PER.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PER.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","market":"AU","secType":"STK","nameCN":"PERCHERON FPO","latestPrice":0.012,"timestamp":1744870320000,"preClose":0.011,"halted":0,"volume":5293913,"delay":0,"nameEN":"PERCHERON FPO","floatShares":739380164,"shares":1087437633,"eps":-0.01595,"marketStatus":"Market Closed","change":0.001,"latestTime":"04-17 16:12:00 AEST","open":0.011,"high":0.012,"low":0.01,"amount":56557,"amplitude":0.181818,"askPrice":0.012,"askSize":4263669,"bidPrice":0.011,"bidSize":3744266,"shortable":3,"etf":0,"ttmEps":-0.01595,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":4.349396349219031,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","floatShares":739380164,"roa":"-51.56%","roe":"-99.00%","lyrEps":-0.013526,"volumeRatio":4.349396349219031,"shares":1087437633,"dividePrice":0,"high":0.012,"amplitude":0.181818,"preClose":0.011,"low":0.01,"week52Low":0.005,"pbRate":"0.85","psRate":"6.80","week52High":0.14,"institutionHeld":0,"latestPrice":0.012,"committee":-0.064861,"eps":-0.01595,"divideRate":0,"volume":5293913,"delay":0,"ttmEps":-0.01595,"open":0.011,"prevYearClose":0.007,"prevWeekClose":0.01,"prevMonthClose":0.011,"prevQuarterClose":0.011,"fiveDayClose":0.01,"twentyDayClose":0.011,"sixtyDayClose":0.009},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PER.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521787521","title":"Ceres Plans to Cut Capital Costs, Boost Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2521787521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521787521?lang=en_us&edition=fundamental","pubTime":"2025-03-24 07:35","pubTimestamp":1742772916,"startTime":"0","endTime":"0","summary":"Ceres (TYO:3696) approved a plan to lower capital costs and boost its stock price at a Friday board meeting, according to a same-day filing on the Tokyo Stock Exchange.The company's 2024 return on equ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PER.AU","IE00B1B80R65.USD","LU0651947912.USD","BK4585","ROE","BK4548","LU0256859116.SGD","LU1515016050.SGD","LU0072463663.USD","LU2462611646.USD","LU1883866441.USD","LU1051768304.USD","LU0651946864.USD","BK7096","LU1051769294.HKD","LU2498475776.HKD","LU0265266980.USD","LU0572108347.SGD","LU0788109048.HKD","LU0106259046.USD","PBR","BK4201","BK4588"],"gpt_icon":0},{"id":"2513271339","title":"BRIEF-Percheron Therapeutics Submits Non-Binding Proposal To In-License New Clinic-Ready Drug Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513271339","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513271339?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:35","pubTimestamp":1740378927,"startTime":"0","endTime":"0","summary":"BRIEF-Percheron Therapeutics Submits Non-Binding Proposal To In-License New Clinic-Ready Drug Development ProgramFeb 24  - Percheron Therapeutics Ltd PER.AX:SUBMITS NON-BINDING PROPOSAL TO IN-LICENSE NEW CLINIC-READY DRUG DEVELOPMENT PROGRAMFurther company coverage: PER.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"gpt_icon":0},{"id":"2513946617","title":"Percheron Therapeutics Submits Non-binding Licensing Proposal for Drug  Development Program, Shares Jump 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513946617","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513946617?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:44","pubTimestamp":1740372286,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics  submitted a non-binding proposal to a pharmaceutical company to in-license a new drug development program focusing on a rare neurological disease, according to a Monday Australian bourse filing.The proposal remains subject to further negotiations, as well as the execution of a definitive agreement, the filing said.The firm estimated that at this stage it would take eight to 12 weeks to negotiate and sign a definitive agreement.It plans to continue to evaluate alternative opportunities in parallel to the proposal.The firm's shares jumped 8% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","PER.AU","LENZ","BK4139"],"gpt_icon":0},{"id":"2513750093","title":"Percheron Therapeutics - Submits Non-Binding Proposal to in-License New Clinic-Ready Drug Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513750093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513750093?lang=en_us&edition=fundamental","pubTime":"2025-02-24 05:02","pubTimestamp":1740344532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nFWN3PD05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","PER.AU"],"gpt_icon":0},{"id":"2508483938","title":"ResMed's half-year FY25 results: solid growth & expanding opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2508483938","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508483938?lang=en_us&edition=fundamental","pubTime":"2025-02-04 12:43","pubTimestamp":1738644202,"startTime":"0","endTime":"0","summary":"ResMed’s  half-year FY25 results reflect a company that is not only thriving in its core business but is also strategically positioned to capitalise on future growth opportunities.The company is currently at the forefront of respiratory healthcare innovation with a market capitalisation of $59 billion at $39 per share. The share price, which has risen 33 per cent over the past year, materially outperformed the ASX 100’s 9.9 per cent gain over the same period, indicating growing investor confidence in the firm’s trajectory.ResMed delivered impressive growth across key metrics for the first half of the 2025 financial year, underscoring sound fundamentals and operational performance.While ResMed recorded US$4.69 billion in sales for FY24, up from US$4.22 billion in FY23, the company is forecast to achieve US$5.25 billion in FY25.ResMed’s improving margins and steady growth underpin its valuation. Using a 12-year average price-to-earnings ratio  of 30 times FY24 EPS, the company’s valuatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/resmed-s-half-year-fy25-results-solid-growth-expanding-opportunities","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/resmed-s-half-year-fy25-results-solid-growth-expanding-opportunities","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7501","LU2177674079.SGD","RMD","BK4504","BK4082","BK7104","FPH.AU","BK4585","BK7096","PER","BK4588","RMD.AU","TAM.AU","BK4567","BK4548","BK7007","LU2008162690.USD","PER.AU"],"gpt_icon":0},{"id":"2503275343","title":"Could 2025 be the year that valuations matter again?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503275343","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503275343?lang=en_us&edition=fundamental","pubTime":"2025-01-13 11:27","pubTimestamp":1736738829,"startTime":"0","endTime":"0","summary":"2024 was a stellar year for equity markets. The performance of US-listed mega-cap tech stocks, particularly the Magnificent 7, has been incredible to watch. While the ASX 300 didn’t managed to keep pace, it still climbed a solid 11.4% in 2024. These returns have been great for investors focused on growth and AI-related thematics, but have made it hard for value investors to keep pace. While 2024 was tough for value managers, could 2025 be the year that investors start to pay attention to the price they pay for stocks again?Past performance is not a reliable indicator of future performance. Source: FactSet; As at 31 December 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/could-2025-be-the-year-that-valuations-matter-again","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/could-2025-be-the-year-that-valuations-matter-again","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7005","XKO.AU","ORI.AU","PER.AU","BK7063","VEA.AU","PER","BK7162","BK7065","BK7017","XJO.AU","XAO.AU","AMC.AU","BK7096","CQR.AU"],"gpt_icon":0},{"id":"2501829452","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2501829452","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501829452?lang=en_us&edition=fundamental","pubTime":"2025-01-07 07:47","pubTimestamp":1736207237,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.West Cobar Metals West Cobar Metals reported \"outstanding\" first-pass flotation test work results at its Bulla Park project in New South Wales, with concentrate one containing over 19% copper and 7.5% antimony.Percheron Therapeutics Percheron Therapeutics received notices from shareholders with over 5% voting rights, who are calling for changes to the company's board of directors, including the removal of two current directors and the election of new ones.Opyl The digital health company partnered with X Firm, formalizing the strategic framework outlined in the memorandum of understanding announced in July 2024. The collaboration aims to support the company's commercial strategy for its TrialKey platform across Europe, the Middle East, Africa, and North America.Gladiator Resources Gladiator Resources confirmed high grades in drill core samples from the Mkuju uranium project","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","OPL.AU","BK7096","BK7095","D3E.AU","GLA.AU","PER.AU","WC1.AU","BK7016"],"gpt_icon":0},{"id":"2491168341","title":"BRIEF-Percheron Therapeutics Seeks Trading Halt Pending In Relation To Initial Top Line Data For Company's Phase IIB Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491168341","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491168341?lang=en_us&edition=fundamental","pubTime":"2024-12-16 09:08","pubTimestamp":1734311302,"startTime":"0","endTime":"0","summary":"BRIEF-Percheron Therapeutics Seeks Trading Halt Pending In Relation To Initial Top Line Data For Company's Phase IIB Clinical TrialDec 16  - Percheron Therapeutics Ltd PER.AX:TRADING HALT PENDING IN RELATION TO INITIAL TOP LINE DATA FOR COMPANY'S PHASE IIB CLINICAL TRIALFurther company coverage: PER.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NE0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","PER.AU"],"gpt_icon":0},{"id":"2491016495","title":"Percheron Therapeutics Ltd - Trading Halt Pending in Relation to Initial Top Line Data for Company's Phase Iib Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491016495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491016495?lang=en_us&edition=fundamental","pubTime":"2024-12-16 06:21","pubTimestamp":1734301267,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241215:nFWN3NE0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PER.AU","BK7096"],"gpt_icon":0},{"id":"2488965212","title":"Percheron Therapeutics Discontinues American Depository Receipt Facility, Uplists to OTCQB","url":"https://stock-news.laohu8.com/highlight/detail?id=2488965212","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488965212?lang=en_us&edition=fundamental","pubTime":"2024-12-03 15:00","pubTimestamp":1733209251,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics  has ended its American Depository Receipt  facility with financial services provider BNY Mellon, according to a Tuesday filing with the Australian bourse.The ADR, trading with the ticker 'ATHJY' will no longer be quoted via over-the-counter  markets, the filing said.The biotechnology company has now uplisted its foreign shares , trading with the ticker 'ATHJF', to the Over-the-Counter Bulletin Board  tier of the OTC markets.The company has applied to the US Financial Industry Regulatory Authority for sponsorship of its F shares and a ticker change from 'ATHJF' to 'PERCF.'These moves are expected to improve access to the company's securities to US investors and reduce costs for the company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFG","BK7096","ADR.AU","BK4117","LENZ","PER.AU","BK4107","BK7094","BK4139"],"gpt_icon":1},{"id":"2488648798","title":"Percheron Therapeutics Advances Phase 2b Muscular Dystrophy Clinical Trial; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488648798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488648798?lang=en_us&edition=fundamental","pubTime":"2024-12-02 12:08","pubTimestamp":1733112485,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics  advanced its phase 2b trial investigating the use of avicursen  in patients with Duchenne muscular dystrophy, according to a Monday filing with the Australian bourse.All 48 patients from the randomized, placebo-controlled trial completed their 25th-week visit, with results expected by the week starting Dec. 16, the filing said. The trial's 12-month study data is anticipated for mid-2025.The company's shares were down almost 3% in recent Monday trade.Price : $0.07, Change: $-0.002, Percent Change: -2.70%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","LU0426417589.USD","BK7096","LU0345774631.USD","LU0994945656.USD","LENZ","LU2238339852.HKD","PER.AU","BK4125","LU1043141123.HKD","AUD","BK4139"],"gpt_icon":1},{"id":"2483663068","title":"Percheron Therapeutics - Completion of Share Purchase Plan to Raise up to a$2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2483663068","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483663068?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:41","pubTimestamp":1731447700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","PER.AU"],"gpt_icon":0},{"id":"2482798223","title":"3 Promising ASX Penny Stocks With Market Caps Over A$70M","url":"https://stock-news.laohu8.com/highlight/detail?id=2482798223","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482798223?lang=en_us&edition=fundamental","pubTime":"2024-11-12 07:04","pubTimestamp":1731366299,"startTime":"0","endTime":"0","summary":"The ASX200 is set to open 0.15% lower today, reflecting mixed performances among US markets, with notable movements in the Dow and tech sector fluctuations impacting investor sentiment. In such a climate, finding stocks with strong fundamentals can be crucial for investors seeking stability and growth potential. Penny stocks, though often overlooked due to their historical reputation, can offer significant opportunities when backed by solid financials; this article will explore three promising examples that stand out for their potential value and growth prospects.Overview: Percheron Therapeutics Limited is an Australian company focused on the research and development of novel antisense pharmaceuticals, with a market cap of A$77.53 million","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-promising-asx-penny-stocks-230459294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["VLS.AU","PRN.AU","BK7088","EVO.AU","BK7055","SHA.AU","XAO.AU","BK7096","XJO.AU","HLO.AU","BRI.AU","NGI.AU","ANG.AU","BK7062","BK7503","BK7132","XKO.AU","BK7016","BK7095","EZZ.AU","BK7077","BK7070","BK7114","MXI.AU","LBL.AU","BK7048","PER.AU","BVS.AU"],"gpt_icon":1},{"id":"2479502212","title":"Is it madness to buy CBA shares now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2479502212","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479502212?lang=en_us&edition=fundamental","pubTime":"2024-10-30 11:40","pubTimestamp":1730259600,"startTime":"0","endTime":"0","summary":"On the surface, it looks as though this Wednesday's session has been a rough one for Commonwealth Bank of Australia (ASX: CBA) shares. At the time of writing, the CBA share price has lost 1.32% of its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/30/is-it-madness-to-buy-cba-shares-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA","BK7096","BK7135","PER.AU","CBA.AU","PER"],"gpt_icon":0},{"id":"2478192134","title":"Percheron Therapeutics Ltd-Percheron Launches Post-Trial Access Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2478192134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478192134?lang=en_us&edition=fundamental","pubTime":"2024-10-28 06:34","pubTimestamp":1730068486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241027:nTUE46TXXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","PER.AU"],"gpt_icon":0},{"id":"2478911301","title":"Percheron Therapeutics Ltd-Share Purchase Plan Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2478911301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478911301?lang=en_us&edition=fundamental","pubTime":"2024-10-28 05:27","pubTimestamp":1730064465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241027:nTUEJC11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PER.AU","BK7096"],"gpt_icon":0},{"id":"2477406397","title":"Percheron Therapeutics Ltd-Percheron to Launch Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2477406397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477406397?lang=en_us&edition=fundamental","pubTime":"2024-10-23 06:37","pubTimestamp":1729636622,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUE56NJ3G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","PER.AU"],"gpt_icon":0},{"id":"2476445944","title":"BRIEF-Percheron Therapeutics Says A$13 Mln Institutional Placement At A$0.08 Per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2476445944","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476445944?lang=en_us&edition=fundamental","pubTime":"2024-10-18 12:19","pubTimestamp":1729225154,"startTime":"0","endTime":"0","summary":"Oct 18 (Reuters) - Percheron Therapeutics Ltd   :   * A$13.0 MILLION INSTITUTIONAL PLACEMENT AT A PRICE OF A$0.08 PER NEW SHARE Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"gpt_icon":0},{"id":"2476495613","title":"BUZZ-Australia's Percheron Therapeutics plunges on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476495613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476495613?lang=en_us&edition=fundamental","pubTime":"2024-10-18 09:01","pubTimestamp":1729213311,"startTime":"0","endTime":"0","summary":"** Shares of Percheron Therapeutics    fall as much as 36.3% to A$0.086, on track for their worst day since March 24, 2010, if current losses hold    ** Stock hits lowest level since Sept. 13   ** Biotech firm says it will raise A$13 mln  via institutional placement at A$0.08 per share, a 40.7% discount to stock's last close    ** Says proceeds will be used to strengthen its financial position, ahead of planned release of data on clinical trial of avicursen to treat Duchenne muscular dystrophy   ** About 17 mln shares change hands, compared with the 30-day average volume of 1.2 mln ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","XKO.AU","BK7096","PER.AU","XAO.AU"],"gpt_icon":0},{"id":"2476452013","title":"Percheron Therapeutics - a$13.0 Mln Institutional Placement at a Price of a$0.08 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2476452013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476452013?lang=en_us&edition=fundamental","pubTime":"2024-10-18 06:24","pubTimestamp":1729203870,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nFWN3LT1KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PER.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PER.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PER.AU\",market:\"AU\",,,undefined,":[]}}